Research programme: anti-cancer gene therapy - Yuhan CorporationAlternative Names: YH21387
Latest Information Update: 13 Jan 2016
At a glance
- Originator Yuhan
- Class Gene therapies
- Mechanism of Action Gene transference
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Discontinued Pancreatic cancer
Most Recent Events
- 13 Jan 2016 Discontinued - Preclinical for Pancreatic cancer in South Korea (Parenteral)
- 16 Dec 2014 Preclinical trials in Pancreatic cancer in South Korea (Parenteral)